<\/p>\n
Rcifax<\/strong> je rifaximin 400 mg or 550 mg<\/strong> — a non-absorbable rifamycin antibiotic that acts almost entirely within the gut lumen. Three validated indications: traveller’s diarrhoea (non-invasive E. coli), prevention of overt hepatic encephalopathy in cirrhosis, and IBS-D (diarrhoea-predominant irritable bowel)<\/strong>. Less than 0.4 percent of an oral dose is absorbed systemically, so off-target side effects, drug interactions, and resistance pressure on commensal bacteria are minimal. WHO-GMP certified manufacturer.<\/p>\n<\/div>\n \ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n Na\u0161e generick\u00e9 l\u00e9ky poch\u00e1zej\u00ed od v\u00fdrobc\u016f certifikovan\u00fdch WHO-GMP a jsou expedov\u00e1ny po cel\u00e9m sv\u011bt\u011b v diskr\u00e9tn\u00edm, nen\u00e1padn\u00e9m balen\u00ed \u2013 na vn\u011bj\u0161\u00ed stran\u011b bal\u00edku nen\u00ed uveden n\u00e1zev l\u00e9ku. Platby kartou jsou sm\u011brov\u00e1ny prost\u0159ednictv\u00edm regulovan\u00e9ho procesoru (popisky na v\u00fdpisu zahrnuj\u00ed regulovan\u00e9ho procesora plateb kartou \u2013 nikdy \u201cMedsBase\u201d nebo n\u00e1zev l\u00e9ku). P\u0159ij\u00edm\u00e1me tak\u00e9 kryptom\u011bny a bankovn\u00ed p\u0159evody SEPA. Ka\u017ed\u00e1 objedn\u00e1vka je zaji\u0161t\u011bna na\u0161\u00ed politikou p\u0159eposl\u00e1n\u00ed.<\/p>\n Rcifax is supplied from a v\u00fdrobce certifikovan\u00e9ho WHO-GMP<\/strong>. Ka\u017ed\u00e1 objedn\u00e1vka je diskr\u00e9tn\u011b zas\u00edl\u00e1na po cel\u00e9m sv\u011bt\u011b a je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> — if it does not arrive within 20 business days, we reship at no cost. Rifaximin is endorsed by AASLD 2021 for hepatic encephalopathy prevention and by ACG 2021 for traveller’s diarrhoea and IBS-D — one of the few antibiotics with strong evidence in functional GI disorders.<\/p>\n Rifaximin binds the β-subunit of bacterial DNA-dependent RNA polymerase (rpoB), inhibiting bacterial RNA synthesis. Spectrum covers Gram-positive and Gram-negative aerobes and anaerobes including E. coli, Shigella, Salmonella, Campylobacter, and many enteric anaerobes. Because absorption is < 0.4 percent of the oral dose, the drug acts effectively only on intra-luminal organisms.<\/p>\nPro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n
Mechanismus \u00fa\u010dinku<\/h2>\n
Indications & doses<\/h2>\n